E7 TCR-T cells
Phase 2Cell therapy
E7 TCR-T cells is one of 37 biologic programs targeting Papilloma. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Papilloma
#DrugCompanyPhaseTrials
1Cervarix
GSKPhase 3
GSK 257049
GSKPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Gardasil
Merck & Co.Phase 3
Engerix-B
GSKPhase 3
Havrix
GSKPhase 3
Fludara
SanofiPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Libtayo
RegeneronPhase 2
Tecentriq
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E7 TCR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- CChristian Hinrichs